Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
帕博利珠单抗+阿昔替尼对比舒尼替尼一线治疗晚期肾透明细胞癌(ccRCC):KEYNOTE-426研究42个月随访结果
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.
全球、随机、安慰剂对照、双盲CANTATA试验的初步分析:在免疫检查点抑制剂或抗血管生成治疗进展的晚期/转移性肾细胞癌患者中,telaglenastat(CB-839)+卡博替尼与安慰剂+卡博替尼的对比
作者:Nizar M. Tannir, et al.
摘要号:4501
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
仑伐替尼+帕博利珠单抗或依维莫司对比舒尼替尼治疗晚期肾细胞癌患者的3期CLEAR试验的健康相关生活质量(HRQoL)分析
作者:Robert J. Motzer, et al.
摘要号:4502
Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.
肌层浸润性膀胱癌(MIBC)患者给予吉西他滨、顺铂+纳武利尤单抗及选择性保留膀胱治疗的2期试验:HCRN GU 16-257
作者:Matt D. Galsky, et al.
摘要号:4503
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
帕博利珠单抗联合吉西他滨和同步大分割放疗作为肌层浸润性膀胱尿路上皮癌(MIBC)的保膀胱治疗:一项多中心2期试验
作者:Arjun V. Balar, et al.
摘要号:4504
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
度伐利尤单抗+tremelimumab+放疗在选择性保留膀胱治疗局限性肌层浸润性膀胱癌(MIBC)患者中的II期试验:IMMUNOPRESERVE-SOGUG试验
作者:Xavier Garcia del Muro, et al.
摘要号:4505
A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
一项比较顺铂+吉西他滨加±berzosertib治疗晚期尿路上皮癌的随机II期研究
作者:Sumanta K. Pal, et al.
摘要号:4507
First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
帕博利珠单抗一线治疗不适合顺铂的晚期尿路上皮癌:2期KEYNOTE-052研究的5年反应和生存结果
作者:Peter H. O’Donnell, et al.
摘要号:4508
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
诱导性T细胞共刺激(ICOS)受体激动剂feladilimab单独或联合帕博利珠单抗:来自INDUCE-1尿路上皮癌扩展队列的结果
作者:Arjun V. Balar, et al.
摘要号:4519